INTERPACE BIOSCIENCES, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that INTERPACE BIOSCIENCES, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.68M | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | $8.20M | Mar 27, 2023 |
| FY2018 | Dec 31, 2018 | $21.90M | Mar 21, 2019 |
| FY2014 | Dec 31, 2014 | $119.94M | Mar 5, 2015 |
| FY2014 | Dec 31, 2013 | $146.53M | Mar 5, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.73M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $46.93M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $12.30M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $12.04M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $10.18M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $40.04M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $9.20M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $11.05M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $9.66M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $31.84M | Apr 1, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $15.90M | Mar 23, 2018 |
| FY2017 | Dec 31, 2016 | $13.09M | Mar 23, 2018 |
| FY2016 | Dec 31, 2015 | $9.43M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $1.47M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $146.53M | Mar 5, 2015 |
| FY2013 | Dec 31, 2012 | $126.90M | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | $157.29M | Mar 15, 2013 |
| FY2011 | Dec 31, 2010 | $134.59M | Mar 9, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.13M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $29.93M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $7.90M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $7.81M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $6.31M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $25.06M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $5.38M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $7.22M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $6.14M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.23M | Apr 1, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.58M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.70M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $1.68M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $2.44M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $708.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $1.95M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | ($186.0K) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $559.0K | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $514.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($21.96M) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.08M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $8.11M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $2.30M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $2.63M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $1.11M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $3.96M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $412.0K | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $1.22M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $838.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($3.62M) | Apr 1, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $642.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $676.0K | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $199.0K | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $146.0K | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $137.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $636.0K | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $149.0K | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $186.0K | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $149.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $703.0K | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.83M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.65M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $3.46M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $1.35M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | ($58.0K) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $3.79M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $2.65M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $1.54M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $1.13M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.69M) | Apr 1, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $356.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $876.0K | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $747.0K | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $225.0K | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $28.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $470.0K | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | $328.0K | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $176.0K | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $65.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $322.0K | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $33.84M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $14.79M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $14.04M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $12.97M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $12.14M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $13.12M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $16.06M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $15.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.98M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $38.43M | Mar 27, 2023 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.48M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $17.01M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $18.04M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $18.71M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $20.37M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $22.12M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $26.21M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $26.84M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $32.52M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $34.31M | Mar 27, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.36M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($2.22M) | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | ($50.54M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | ($52.28M) | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | ($54.77M) | Mar 31, 2025 |
| FY2025 | Dec 31, 2023 | ($55.54M) | Mar 30, 2026 |
| FY2024 | Sep 30, 2023 | ($56.72M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | ($56.68M) | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | ($57.39M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | ($58.09M) | Mar 31, 2025 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $8.43M | Mar 31, 2022 |
| FY2021 | Dec 31, 2020 | $8.43M | Mar 31, 2022 |
| FY2021 | Dec 31, 2019 | $8.43M | Mar 31, 2022 |
| FY2019 | Jul 15, 2019 | $8.30M | Apr 22, 2020 |
| FY2015 | Dec 31, 2015 | $0 | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $15.55M | Mar 30, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 5, 2015 |
| FY2013 | Dec 31, 2012 | $2.52M | Mar 6, 2014 |
| FY2012 | Dec 31, 2011 | $18.91M | Mar 15, 2013 |
| FY2011 | Dec 31, 2010 | $23.98M | Mar 9, 2012 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($210.81M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($235.38M) | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | ($237.26M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | ($238.94M) | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | ($241.37M) | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | ($242.08M) | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | ($242.96M) | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | ($243.52M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($249.02M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($227.06M) | Mar 27, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.51M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $1.46M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | $2.11M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | $2.02M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | $2.81M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $3.50M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | $5.08M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | $5.60M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $4.83M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $2.67M | Mar 27, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.43M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 4.41M | Mar 30, 2026 |
| FY2024 | Sep 30, 2024 | 4.40M | Mar 31, 2025 |
| FY2024 | Jun 30, 2024 | 4.38M | Mar 31, 2025 |
| FY2024 | Mar 31, 2024 | 4.38M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 4.35M | Mar 31, 2025 |
| FY2024 | Sep 30, 2023 | 4.32M | Mar 31, 2025 |
| FY2024 | Jun 30, 2023 | 4.31M | Mar 31, 2025 |
| FY2024 | Mar 31, 2023 | 4.31M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 4.30M | Apr 1, 2024 |